Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Men with localized prostate cancer benefit from intensity modulated radiation therapy

Men with localized prostate cancer treated with a newer technology, intensity modulated radiation therapy (IMRT), have more than a quarter (26 percent) fewer late bowel and rectal side effects and a statistically improved lower dose of radiation to the bladder and rectum, compared to those who undergo 3D-CRT, according to a randomized study presented at the plenary session October 3, 2011, at the 53rd Annual Meeting of the American Society for Radiation Oncology.

27 Sep 2011

Photocure, Ipsen partner to commercialise Hexvix for diagnosis of bladder cancer

Ipsen announces today a partnership with Photocure, a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology.

27 Sep 2011

Men over 75 with prostate cancer are being undertreated: Study

It's an ongoing debate: Should men over a certain age be treated for prostate cancer? Should these patients be submitted to treatments that may result in significant side effects if they may not live very much longer?

27 Sep 2011

World's first treatment of metastasized brain cancer uses IsoRay's Cesium-131 brachytherapy seeds

IsoRay, a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced today that doctors at New York Presbyterian Hospital/ Weill Cornell Medical Center have performed the world's first treatment of metastasized brain cancer using IsoRay's Cesium-131 brachytherapy seeds.

26 Sep 2011

Positive interim data from Aeterna Zentaris' AEZS-108 Phase 1/2 study on prostate cancer

Aeterna Zentaris Inc., today announced positive interim data for the Phase 1 portion of its ongoing Phase 1/2 study in castration and taxane-resistant prostate cancer with its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108.

26 Sep 2011

Ibandronate controls pain in prostate cancer patients with bone metastases

Many prostate cancer patients develop bone metastases, and controlling the pain these cause can be difficult. Now the first large randomised Phase III trial of a bisphosphonate drug in these patients has shown that a single dose of the drug is as good for pain relief as single dose radiotherapy, the standard treatment for bone metastases. Results of the trial were presented at the 2011 European Multidisciplinary Cancer Congress.

26 Sep 2011

Couples counseling can benefit prostate cancer patients' sex lives

Both internet-based counseling programs and face-to-face therapy sessions for couples improve the sex lives of prostate cancer survivors and their spouses. That is the finding of a new study published early online in Cancer, a peer-reviewed journal of the American Cancer Society.

26 Sep 2011

Combination of abiraterone acetate, prednisone reduces fatigue in men with prostate cancer

Men with prostate cancer that has spread to other parts of the body and that is resistant to hormone therapy suffer less from fatigue if they are treated with a combination of abiraterone acetate and prednisone, according to results from a phase III clinical trial presented today.

26 Sep 2011

Genetic testing for breast and ovarian cancer

Experts from Cancer Treatment Centers of America (CTCA) provide some clues as to who should be using these tests. They explain that women who have been diagnosed with cancer and/or people who have a strong family history of cancer can consider genetic testing. Red flags to consider are anyone in the family who developed cancer at a young age, multiple family members who developed cancer, if a person experienced bilateral cancer (cancer in both breasts), breast and ovarian cancer in the same woman, or cancer appeared where it wasn’t expected (like breast cancer in men)

26 Sep 2011

Regeneron announces additional data from aflibercept Phase 3 trial on colorectal cancer

Regeneron Pharmaceuticals, Inc. today announced that additional data from the Phase 3 VELOUR trial will be presented at the 2011 European Multidisciplinary Cancer Congress (EMCC) which will take place from September 23-27 in Stockholm, Sweden.

26 Sep 2011

First Radium-223 Chloride Phase III study in prostate cancer

Until recently, options for patients with bone metastases from advanced prostate cancer have been very limited. But now the first Phase III study of an alpha-pharmaceutical in these patients has shown that it can prolong survival significantly, according to research reported today (Saturday) at the 2011 European Multidisciplinary Cancer Congress.

26 Sep 2011

Complications requiring hospitalization after prostate biopsy rise: Study

In a study of complication rates following prostate biopsy among Medicare beneficiaries, Johns Hopkins researchers have found a significant rise in serious complications requiring hospitalization.

23 Sep 2011

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Amgen announced today that data from XGEVA (denosumab) and Vectibix (panitumumab) studies will be presented at the 2011 European Multidisciplinary Cancer Congress, Sept. 23 - 27, 2011, in Stockholm, Sweden.

23 Sep 2011

UCLA's gene-based imaging system can accurately detect metastatic prostate cancers

Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed a way to image the spread of a particularly dangerous form of prostate cancer earlier than conventional imaging in use today, which may allow oncologists to find and treat these metastases more quickly and give patients a better chance at survival.

23 Sep 2011

Adeno-associated virus type 2 kills human breast cancer cells in lab

A nondisease-causing virus kills human breast cancer cells in the laboratory, creating opportunities for potential new cancer therapies, according to Penn State College of Medicine researchers who tested the virus on three different breast cancer types that represent the multiple stages of breast cancer development.

23 Sep 2011

Adamis receives patents for APC-200 prostate cancer drug in South Africa, Singapore

Adamis Pharmaceuticals Corporation, today announced the technology which constitutes its compound APC-200 was recently granted patents in Singapore and South Africa. These patents significantly strengthen the Adamis APC-200 patent portfolio for the use of APC-200 in the treatment of early and late stage prostate cancer.

23 Sep 2011

MD Anderson professor wins 2011 Julie and Ben Rogers Award for Excellence in Prevention

Lorna McNeill, Ph.D., assistant professor in the Department of Health Disparities Research at The University of Texas MD Anderson Cancer Center, is the recipient of the 2011 Julie and Ben Rogers Award for Excellence in Prevention.

22 Sep 2011

Impotence after prostate cancer treatment

According to researchers patients undergoing treatment for prostate cancer could be at a risk of impotence. According to the new study, published in the Journal of the American Medical Association there may be a formula to help gauge those risks for three common types of treatment, including surgery and radiation.

21 Sep 2011

Prediction models may effectively identify erectile function after prostate cancer surgery

The development of prediction models that included variables such as pretreatment sexual function, patient characteristics and treatment factors appear to be effective at predicting erectile function 2 years after prostatectomy, external radiotherapy, or brachytherapy for prostate cancer, according to a study in the September 21 issue of JAMA.

21 Sep 2011

African-American men living in low sunlight areas more likely to have Vitamin D deficiency

African-American men living in areas with low sunlight are up to 3 - times more likely to have Vitamin D deficiency than Caucasian men and should take high levels of Vitamin D supplements, according to a new study from Northwestern University Feinberg School of Medicine.

21 Sep 2011

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Men with localized prostate cancer benefit from intensity modulated radiation therapy

Photocure, Ipsen partner to commercialise Hexvix for diagnosis of bladder cancer

Men over 75 with prostate cancer are being undertreated: Study

World's first treatment of metastasized brain cancer uses IsoRay's Cesium-131 brachytherapy seeds

Positive interim data from Aeterna Zentaris' AEZS-108 Phase 1/2 study on prostate cancer

Ibandronate controls pain in prostate cancer patients with bone metastases

Couples counseling can benefit prostate cancer patients' sex lives

Combination of abiraterone acetate, prednisone reduces fatigue in men with prostate cancer

Genetic testing for breast and ovarian cancer

Regeneron announces additional data from aflibercept Phase 3 trial on colorectal cancer

First Radium-223 Chloride Phase III study in prostate cancer

Complications requiring hospitalization after prostate biopsy rise: Study

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

UCLA's gene-based imaging system can accurately detect metastatic prostate cancers

Adeno-associated virus type 2 kills human breast cancer cells in lab

Adamis receives patents for APC-200 prostate cancer drug in South Africa, Singapore

MD Anderson professor wins 2011 Julie and Ben Rogers Award for Excellence in Prevention

Impotence after prostate cancer treatment

Prediction models may effectively identify erectile function after prostate cancer surgery

African-American men living in low sunlight areas more likely to have Vitamin D deficiency

What to know about prostate cancer eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in